Browse

Presence of Membrane-Bound TGF-β1 and Its Regulation by IL-2-Activated Immune Cell-Derived IFN-γ in Head and Neck Squamous Cell Carcinoma Cell Lines

DC Field Value Language
dc.contributor.authorAhn, Yong-Oon-
dc.contributor.authorLee, June-Chul-
dc.contributor.authorSung, Myung-Whun-
dc.contributor.authorHeo, Dae Seog-
dc.date.accessioned2012-05-24T06:31:36Z-
dc.date.available2012-05-24T06:31:36Z-
dc.date.issued2009-05-15-
dc.identifier.citationJOURNAL OF IMMUNOLOGY; Vol.182 10; 6114-6120ko_KR
dc.identifier.issn0022-1767-
dc.identifier.urihttps://hdl.handle.net/10371/76425-
dc.description.abstractThe presence of membrane-bound TGF-beta 1 (mTGF-beta 1) has been recently observed in regulatory T cells, but only a few studies have reported the same phenomenon in cancer cells. In this study, we investigate the regulation of mTGF-beta l expression in five head and neck squamous cell carcinoma cell lines using FACS analysis. Through blocking Ab and exogenous cytokine treatment experiments, we found that expression of mTGF-beta 1 is significantly induced by the activated immune cell-derived factor IFN-gamma. In addition, IFN-gamma and TNF-alpha are shown to have a synergistic effect on mTGF-beta 1 expression. Moreover, we found that exogenous TNF-alpha induces endogenous TNF-alpha mRNA expression in an autocrine loop. In contrast to previous reports, we confirm that, in this model, mTGF-beta 1 is neither a rebound form of once-secreted TGF-beta 1 nor an activated form of its precursor membrane latency-associated peptide. Inhibitors of transcription (actinomycin D), translation (cycloheximide), or membrane translocation (brefeldin A) effectively block the induction of mTGF-beta 1, which suggests that induction of mTGF-beta 1 by IFN-gamma and/or TNF-alpha occurs through de novo synthesis. These findings suggest that some cancer cells can detect immune activating cytokines, such as IFN-gamma and TNF-alpha, and actively block antitumor immunity by induction of mTGF-beta 1. The Journal of Immunology, 2009, 182: 6114-6120.ko_KR
dc.description.sponsorshipThis study was supported by grants from the Innovative Research Institute for Cell
Therapy (A062260) and the Korea Health 21 Research & Development Project (02-
PJ1-PG3-21206-0003), Ministry of Health and Welfare, Republic of Korea.
ko_KR
dc.language.isoenko_KR
dc.publisherAMER ASSOC IMMUNOLOGISTSko_KR
dc.titlePresence of Membrane-Bound TGF-β1 and Its Regulation by IL-2-Activated Immune Cell-Derived IFN-γ in Head and Neck Squamous Cell Carcinoma Cell Linesko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor안용운-
dc.contributor.AlternativeAuthor이준철-
dc.contributor.AlternativeAuthor성명훈-
dc.contributor.AlternativeAuthor허대석-
dc.identifier.doi10.4049/jimmunol.0803725-
dc.citation.journaltitleJOURNAL OF IMMUNOLOGY-
dc.description.citedreferenceVila-del Sol V, 2008, J IMMUNOL, V181, P4461-
dc.description.citedreferenceAndersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308-
dc.description.citedreferenceTurley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089-
dc.description.citedreferenceBaker K, 2008, INT J CANCER, V122, P1695, DOI 10.1002/ijc.23312-
dc.description.citedreferenceMarigo I, 2008, IMMUNOL REV, V222, P162-
dc.description.citedreferenceTeicher BA, 2007, CLIN CANCER RES, V13, P6247, DOI 10.1158/1078-0432.CCR-07-1654-
dc.description.citedreferenceLim DS, 2007, CANCER IMMUNOL IMMUN, V56, P1817, DOI 10.1007/s00262-007-0325-0-
dc.description.citedreferenceWrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157-
dc.description.citedreferenceFilipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829-
dc.description.citedreferenceGandhi R, 2007, J IMMUNOL, V178, P4017-
dc.description.citedreferenceYu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995-
dc.description.citedreferenceMenoret A, 2006, J IMMUNOL, V177, P6091-
dc.description.citedreferencePatterson SG, 2006, ONCOGENE, V25, P6113, DOI 10.1038/sj.onc.1209632-
dc.description.citedreferenceJakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2-
dc.description.citedreferenceBroderick L, 2006, J IMMUNOL, V177, P3082-
dc.description.citedreferenceRobinson CM, 2006, CYTOKINE, V35, P53, DOI 10.1016/j.cyto.2006.07.007-
dc.description.citedreferenceHanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.2006.0436-
dc.description.citedreferenceDasgupta S, 2006, J CELL BIOCHEM, V97, P1036, DOI 10.1002/jcb.20647-
dc.description.citedreferenceSmyth MJ, 2006, J IMMUNOL, V176, P1582-
dc.description.citedreferenceBui JD, 2006, J IMMUNOL, V176, P905-
dc.description.citedreferenceLi MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737-
dc.description.citedreferenceKulbe H, 2005, CANCER RES, V65, P10355, DOI 10.1158/0008-5472.CAN-05-0957-
dc.description.citedreferenceThomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012-
dc.description.citedreferenceGhiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511-
dc.description.citedreferenceDasgupta S, 2005, J IMMUNOL, V175, P5541-
dc.description.citedreferenceHagemann T, 2005, J IMMUNOL, V175, P1197-
dc.description.citedreferenceVILADELSOL V, 2005, J IMMUNOL, V174, P2825-
dc.description.citedreferenceBalkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388-
dc.description.citedreferenceLu SL, 2004, CANCER RES, V64, P4405-
dc.description.citedreferenceLee JC, 2004, J IMMUNOL, V172, P7335-
dc.description.citedreferenceNakamura K, 2004, J IMMUNOL, V172, P834-
dc.description.citedreferenceWilliams L, 2004, J IMMUNOL, V172, P567-
dc.description.citedreferenceLeu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084-
dc.description.citedreferenceRoberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100-
dc.description.citedreferenceCastriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730604100-
dc.description.citedreferenceDong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730-
dc.description.citedreferenceKarin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780-
dc.description.citedreferenceNiu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj/onc/1205260-
dc.description.citedreferenceNakamura K, 2001, J EXP MED, V194, P629-
dc.description.citedreferenceHasegawa Y, 2001, CANCER, V91, P964-
dc.description.citedreferenceGrainger DJ, 2000, CYTOKINE GROWTH F R, V11, P133-
dc.description.citedreferenceKim SJ, 2000, CYTOKINE GROWTH F R, V11, P159-
dc.description.citedreferenceKhalil N, 1999, MICROBES INFECT, V1, P1255-
dc.description.citedreferenceKu JL, 1999, LARYNGOSCOPE, V109, P976-
dc.description.citedreferenceMunger JS, 1999, CELL, V96, P319-
dc.description.citedreferenceWikstrom P, 1998, PROSTATE, V37, P19-
dc.description.citedreferenceFakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909-
dc.description.citedreferenceHEO DS, 1989, CANCER RES, V49, P5167-
dc.description.tc3-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse